Related Experiment Video
Updated: Aug 17, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Soluble p185(HER-2) in patients with malignant bone tumours
G Holzer1, T Pfandlsteiner, M Koschat
1Department of Orthopaedics, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. gerold.holzer@meduniwien.ac.at
Background:
This study was initiated to test the hypothesis that soluble p185(HER-2) could be of value as a diagnostic or predictive marker for patients with malignant bone tumours.
Procedure:
Sera of 35 patients with high-grade malignant osteosarcoma (n = 27) and Ewing Sarcoma (n = 8) were tested at the time of diagnosis by ELISA and compared with sera of controls (n = 38) and clinical data.
Results:
In patients with osteosarcoma and Ewing Sarcoma, levels of sp185(HER-2) did not differ significantly from levels in controls. These results were irrespective of the type of tumour, survival chemotherapy or other clinical variables.
Conclusion:
p185(HER-2) serum levels do not appear to be of diagnostic or predictive value for differentiation of high-grade osteosarcoma and Ewing Sarcoma.
